FDA Layoffs Slow Overseas Drug Inspections

The FDA’s recent layoffs are causing delays in the inspection of overseas drug manufacturers. This slowdown raises concerns about medication safety. ProPublica reported on July 7 that the FDA has let go of dozens of individuals responsible for coordinating complex inspections abroad. Although some staff have been rehired, the disruption continues to affect the inspection process. Current and former employees worry that these delays could compromise the safety of medications imported into the U.S. The situation highlights the critical role of FDA inspections in ensuring drug safety and the potential risks posed by staffing cuts.